Tandem Therapeutics’ Post

Turn Therapeutics Topical Atopic Dermatitis Candidate Significantly Inhibits Key Cytokines in Expansion Study of Flagship Formula https://lnkd.in/gYCdgyXM – Significant reduction of key cytokines IL-31, IL-36α, and IL-36γ – ISGA mean score of 0.83 with GX-03 topical pre-treatment vs 2.44 placebo, comparable to biologics – Company projects phase 1b/2 efficacy trials to begin [...]

AbbVie to acquire Nimble Therapeutics in $200m deal The deal will provide AbbVie access to Nimble's proprietary peptide synthesis platform, which facilitates the discovery and optimisation of oral peptide therapeutics. Read more: https://lnkd.in/eXbg4W8f #pharmaindustry #pharmaceuticalindustry #peptidesynthesis #peptidethrapeutics #abbvie #nimbletherapeutics #worldpharma

Recently, oligonucleotides have been widely developed in the biopharmaceutical industry for use as human drugs, both as therapeutics and as vaccines. Oligonucleotides encompass a wide range of sizes and products including small interfering RNAs (siRNA) and microRNA (miRNA) products, plasmid DNA (pDNA), and messenger RNA (mRNA) vaccines. Learn more about the challenge of analytical testing oligonucleotide products and the different levels of support required from William Boomershine, Ph.D. in his newest whitepaper, Navigating the Analytical Complexity of Oligonucleotide Therapeutics ➡️https://hubs.li/Q02HNR9q0 #labservices #askalcami #alcami #oligonucleotide #analytical #CDMO

AbbVie Completes Acquisition of Nimble Therapeutics https://lnkd.in/gDF5B8nE Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie’s pipeline and R&D capabilities NORTH CHICAGO, Ill., Jan. 23, 2025 /PRNewswire/ — [...]

Partners invite proposals for multi-functional biologics research Daiichi Sankyo and German research institute BioMed X Institute have agreed a new partnership to advance the development of bi- and multi-specific biologics for treating solid tumours. https://lnkd.in/egV7iTM2 #BiologicsResearch #BispecificAntibodies #SolidTumours

Assessment of Fc-mediated Functional Activity for the Development of Complex Biologics and Bioconjugates, Upcoming Webinar Hosted by Xtalks https://lnkd.in/gCbia8jZ In this free webinar, learn the best approaches to assess Fc function (antibody-dependent cellular cytotoxicity [ADCC], antibody-dependent cellular phagocytosis [ADCP] and complement-dependent cytotoxicity [CDC]) for drug discovery and development programs. Attendees will gain insights… Click [...]

Exosome Diagnostics Market worth $2,347 Million by 2029 Globally, at a CAGR of 108.9%, says MarketsandMarkets™ 🔗https://lnkd.in/d2ESUUZ4 The global exosome diagnostics and therapeutics market is anticipated to expand significantly, increasing from USD 59 million in 2024 to USD 2,347 million by 2029, reflecting a compound annual growth rate (CAGR) of 108.9%. However, the launch of exosome-based therapeutics is expected to commence from 2029 onward. Overall, the market, valued at USD 59 million in 2024, is projected to reach USD 6,848 million by 2032, growing at a CAGR of 81.2% from 2024 to 2032. Bio-Techne, NanoFCM, System Biosciences, Capital Biosciences, AMSBIO, INOVIQ Ltd (ASX:IIQ), Direct Biologics, Regeneus Ltd, Curexsys GmbH i.L., Aegle Therapeutics, Mercy BioAnalytics, Inc., NanoSomix, Inc., Exonox Biosciences, Inc. 胞泌體生技, Capricor Therapeutics, Inc., Evox Therapeutics Ltd

Researchers at the University of Cambridge are developing a new type of orally administered biologics (pills) to treat IBD and they need your help. They are trying to gain a better understanding of current issues faced by IBD patients with their current treatments in order to support their research and their aim of improving the way IBD is treated. If you have IBD, please take the survey here to help shape this research: https://lnkd.in/giQj3smy

𝐄𝐱𝐨𝐬𝐨𝐦𝐞 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐰𝐨𝐫𝐭𝐡 $2,347 𝐌𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2029 𝐆𝐥𝐨𝐛𝐚𝐥𝐥𝐲, 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 108.9%, 𝐬𝐚𝐲𝐬 𝐌𝐚𝐫𝐤𝐞𝐭𝐬𝐚𝐧𝐝𝐌𝐚𝐫𝐤𝐞𝐭𝐬™ 🔗https://lnkd.in/d-ivgmvf The global exosome diagnostics and therapeutics market is anticipated to expand significantly, increasing from USD 59 million in 2024 to USD 2,347 million by 2029, reflecting a compound annual growth rate (CAGR) of 108.9%. However, the launch of exosome-based therapeutics is expected to commence from 2029 onward. Overall, the market, valued at USD 59 million in 2024, is projected to reach USD 6,848 million by 2032, growing at a CAGR of 81.2% from 2024 to 2032. Bio-Techne, NanoFCM, System Biosciences, Capital Biosciences, AMSBIO, INOVIQ Ltd (ASX:IIQ), Direct Biologics, Regeneus Ltd, Curexsys GmbH i.L., Aegle Therapeutics, Mercy BioAnalytics, Inc., NanoSomix, Inc., Exonox Biosciences, Inc. 胞泌體生技, Capricor Therapeutics, Inc., Evox Therapeutics Ltd

Curia biologics will be at #AET in December in SD. Whether you are interested in discovering a therapeutic mab or multispecific for your novel targets or you are interested in generating a rather difficult anti-Id antibody for clinical assays, we have the right team and customized solutions for you. Stop by our booth or schedule a meeting with us hear our approaches to tackle your specific challenge. Check out our poster while you are there. #antibody #multispecific #bispecific #biologics #antibodydiscovery #antibodyengineering #humanization